A major contributor to the lack of medicines in developing countries is an intellectual property regime that allows proprietary drug companies with intellectual property monopolies to charge high prices and maximize profit.
Since 1995, the American Academy of Neurology has provided guidelines for brain death determination, but nationwide adherence to these guidelines has been incomplete.
AMA J Ethics. 2020; 22(12):E1027-1032. doi:
10.1001/amajethics.2020.1027.